ADAM10 and cholangiocarcinoma: The expression of ADAM10 in cholangiocarcinoma (CHOL) and liver cancer (LIHC) showed no statistically significant difference from that in normal bile ducts and livers but was significantly increased in other digestive system tumors (Figure 2C).